About Generation Bio
Generation Bio focuses on developing genetic treatments for both rare and common diseases. Their main product is based on a non-viral genetic medicine platform that includes iqDNA, which is designed to be immune-quiet, and ctLNP, a delivery system that targets specific cells. This platform allows for the delivery of large amounts of genetic material to particular tissues, aiming for long-lasting effects from a single treatment. They use a unique manufacturing process called rapid enzymatic synthesis (RES) that enables them to produce these treatments at scale, potentially reaching hundreds of millions of doses. Unlike many competitors, Generation Bio's approach allows for redosing and adjusting treatment levels based on patient needs. The company's goal is to make genetic medicine more accessible and to address significant medical needs in the population.